Amniotic products are the amniotic tissues and their parts that are used to provide protection and support for the injured tissue and other body parts. The amniotic membrane and suspension are two products that can be used for treatment. The amniotic membrane is the innermost layer of the placenta that nourishes and maintains an unborn child. Amniotic fluid is the liquid that surrounds the baby until delivery. The rising incidences of burn injuries led to the increased use of amniotic products for its treatment.
MiMedx and Smith & Nephew – Notable Market Players in Amniotic Products Market
The Amniotic Products market majorly consists of the players such as MiMedx; Smith & Nephew; Integra Lifesciences; Stryker; Organogenesis, Inc.; Katena Products, Inc.; NuVision Biotherapies Ltd, Lucina Biosciences; and Next Biosciences. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the amniotic products market:
| Year | News |
| May-2022 | MiMedx Group received a $4.6 Million award to evaluate PURION processed Dehydrated Human Amnion Chorion Membrane (DHACM) as an advanced treatment option for wound and burn care. The award from the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium collaborating under Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command, is sponsored and will be managed by the Naval Medical Research Center (NMRC) to advance medical treatments for combat wounds and burns. |
| Jun-2021 | MiMedx Group, Inc. announced the publication of its peer-reviewed study in the Journal of Investigative Dermatology (JID) Innovations, addressing the potential utility of MiMedx Purion-processed human amniotic/chorionic membrane (dHACM) dehydrated in combating complications of excessive fibrosis, a pathological process central to a number of serious unmet medical needs. It is estimated that more than 100 million people worldwide suffer from pathological scarring each year, including hypertrophic and keloid scarring, with long-term effects ranging in severity from minor cosmetic defects to significantly compromised tissue architecture and dysfunction in a range of conditions. Product development and innovation will strengthen the product portfolio. |
| May-2021 | MiMedx Group announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM) to develop and advance scientific evidence in support of safe and effective clinical therapies. The partnership reflects a shared vision to advance regenerative science and innovative biologics that restore quality of life for patients and is geared to further understanding product mechanisms of action and potential therapeutic targets. |
| Feb-2021 | Stryker completed the acquisition of Wright Medical, Inc. a global medical device company focused on extremities and biologics. This acquisition strengthens global market position in trauma and extremities, providing significant opportunities to drive innovation and reach more patients. |
| Jan-2021 | The acquisition of ACell and its proprietary MatriStem UBM technologies will position Integra to offer more comprehensive complex wound management solutions to address our customers’ most pressing clinical challenges |
| Jan-2020 | Integra LifeSciences Holdings Corporation entered into a definitive agreement to acquire ACell, Inc. (ACell) for a $300 million cash upfront payment at closing subject to customary purchase price adjustments and cash payments of up to an additional $100 million upon achievement of certain revenue growth milestones. ACell is an innovative regenerative medicine company with a product portfolio based on MatriStem UBM, a proprietary porcine bladder matrix platform technology. The transaction is expected to close in the first quarter of 2021, subject to the satisfaction of customary conditions, including regulatory approvals. The acquisition of ACell is the next step in expanding Integras’ Orthopedics and Tissue Technologies (OTT) segment. Following the completion of the previously announced sale of Integras’ orthopedic business, which is expected to occur in early January, OTT will be referred to as the Tissue Technologies segment. |
